Showing results (911-920 of 1,191) with videos related to
Sort By:
Pageof 120
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.Proceedings of the National Academy of Sciences of the United States of America|February 22, 2018
Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesisHuiyuan Zhang, Haiyan S Li, Emily J Hillmer, et al.Clinical Lymphoma, Myeloma & Leukemia|August 10, 2014
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemiaNaveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, et al.Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.Cell Stem Cell|November 3, 2018
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic ChemotherapyJoanne I Hsu, Tajhal Dayaram, Ayala Tovy, et al.Pageof 120